Innovative Targeting Solutions Inc. announces the issuance of two European patents applying the HuTARG™ platform to targeted mutagenesis and the engineering of functional agonists to GPCRs

Vancouver, BC – October 21, 2019 – Innovative Targeting Solutions Inc., a leader in V(D)J based protein engineering, today announced the issuance of two European patents. The patents, “G-Protein Coupled Receptor Agonists and Methods” issued on August 14, 2019 and “Generating Targeted Sequence Diversity in Proteins” issued on August 21, 2019, each a breakthrough in the engineering of biologics and together offer transformative opportunities in the engineering of biologics to GPCRs.

GPCRs are an historically difficult target class to engineer effective biologics. As a multi-spanning membrane protein, they are challenging to purify as the structure of the protein is integral with the membrane. Although artificial methods exist, the preferred target is the molecule as it is expressed in the mammalian cell membrane, and even more preferable is the ability to assay the GPCR directly for function. Unlike phage and yeast display systems, a functional assay can be incorporated into the HuTARG cell, a mammalian line, allowing for the interrogation of a billion unique antibody molecules in a single day by the use of high speed FACS sorting. Essentially the functional assay is at the level of a single cell; a billion cells assayed by traditional 384 well plates would require over two and half million plates and years of work even with the most advanced robotic systems.

“These are Innovative Targeting Solutions’ eighth and ninth issued patents on the HuTARG platform, a testament to its truly disruptive nature as a biologics discovery platform”, said Paul Kang, Innovative Targeting Solutions Inc. CSO.

About Innovative Targeting Solutions Inc.
Founded in 2008, Innovative Targeting Solutions Inc. is a privately-held company that has developed a next generation protein engineering platform for the generation of fully human antibody and T cell receptor based therapeutics using its proprietary HuTARG™ technology. The HuTARG™ technology is a fully mammalian technology that generates diversity in vitro via RAG1/RAG2 mediated V(D)J recombination. For more information, visit

Paul Kang, CSO Innovative Targeting Solutions